Dr. Agarwal's Eye Hospital Limited share price
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, corneal ulcer, fungal keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, pinhole …Read more
- Market Cap₹ 2,454 Cr.
- Current Price₹ 5,077.00
- High / Low₹ 5,500 / 5,036
- Stock P/E32.0
- Book Value₹ 716
- Dividend Yield0.15 %
- ROCE16.1 %
- ROE25.20 %
- Face Value—
More figures (10)
- EPS (TTM)₹ 158.78
- Price / Book7.09
- OPM21.7 %
- Debt / Equity0.94
- Sales growth (4Y)20.8 %
- Profit growth (4Y)23.8 %
- Promoter holding82.3 %
- EV / EBITDA17.2
- Beta-0.54
- All-time high₹ 5,500
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| DRAGARWQ | -3.65% | — | — | — | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Dr. Agarwal's Eye Hospital Limited is in the Medical Care Facilities industry (Healthcare), with a market value of ₹2,454 crore.
- It trades at 32.0 times its last 12 months' earnings and 7.1 times book value.
- Revenue grew 20.8% a year over the last 4 years, profit 23.8% a year.
- Return on equity was 25.2% and return on capital employed 16.1% in the latest year.
- Debt was 0.94 times shareholders' equity.
- The share price is 7.7% below its 52-week high.
- Promoters and insiders hold about 82.3%; institutions about 1.8%.
Pros
AI- Strong return on equity: 29.8% on average over the last 3 years.
Cons
AINo standout weaknesses in the reported figures.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Dr. Agarwal's Eye Hospital Limited
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, corneal ulcer, fungal keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, pinhole pupilloplasty, rosette cataract, and congenital glaucoma. It also operates opticals and pharmacies and is engaged in the sale of optical frames, contact lenses, accessories, and pharmaceutical product…
- Employees
- 1,356
- Head office
- Chennai
Peer comparison
HealthcareMedical Care Facilities
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Dr. Agarwal's Eye Hospital | 5,077.00 | 32.0 | 2,454 | 0.15 | 23 | 35.46 | 143 | 22.28 | 16.1 | 25.2 | 7.09 | 21.7 | 0.94 | 82.33 | 470 | 20.8 |
| 2. | Apollo Hospitals Enterprise | 7,890.00 | 54.3 | 1,13,446 | 0.25 | 610 | 38.41 | 7,044 | 20.56 | 19.2 | 21.9 | 11.97 | 11.7 | 0.90 | 28.39 | 25,229 | 14.8 |
| 3. | Max Healthcare Institute | 846.00 | 56.7 | 82,342 | 0.23 | 323 | 4.87 | 2,366 | 16.70 | 12.6 | 14.3 | 7.66 | 22.8 | 0.32 | 28.20 | 8,225 | 22.4 |
| 4. | Aster DM Quality Care | 674.35 | 109.3 | 58,781 | 0.44 | 29 | -68.70 | 1,311 | 21.60 | 9.4 | 9.7 | 7.59 | 14.2 | 0.49 | 64.26 | 4,643 | 15.7 |
| 5. | Fortis Healthcare | 736.50 | 53.1 | 55,603 | 0.13 | 266 | 2.35 | 2,545 | 17.46 | 11.9 | 11.1 | 5.62 | 17.8 | 0.35 | 35.19 | 9,048 | 13.3 |
| 6. | Narayana Hrudayalaya | 1,719.40 | 42.5 | 34,921 | 0.26 | 207 | 5.37 | 2,684 | 78.05 | 11.4 | 19.7 | 7.70 | 15.5 | 1.29 | 67.23 | 7,896 | 20.5 |
| 7. | Global Health | 1,240.00 | 60.0 | 33,322 | 0.04 | 159 | -0.18 | 1,304 | 26.50 | 15.0 | 15.1 | 8.41 | 16.8 | 0.30 | 66.39 | 4,318 | 17.2 |
| 8. | Krishna Institute of Medical Sciences | 685.60 | 134.4 | 28,796 | 0.00 | 42 | -47.20 | 1,180 | 35.33 | 8.1 | 11.0 | 12.21 | 13.8 | 1.89 | 41.74 | 3,872 | 21.3 |
| 9. | Rainbow Children's Medicare | 1,248.90 | 44.4 | 12,634 | 0.28 | 63 | 16.23 | 470 | 33.17 | 16.8 | 17.9 | 7.69 | 23.7 | 0.54 | 52.29 | 1,703 | 13.1 |
| 10. | Park Medi World | 235.70 | 35.9 | 10,181 | 0.00 | 89 | — | 476 | — | 17.9 | 16.8 | 4.64 | 23.3 | 0.18 | 83.94 | 1,679 | 9.6 |
| Median: 17 Co. | 1,043.00 | 50.2 | 10,181 | 0.13 | 124 | 4.87 | 1,307 | 22.28 | 13.8 | 16.3 | 7.59 | 16.8 | 0.52 | 58.28 | 4,481 | 17.2 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Sales | 100 | 117 | 116 | 120 | 143 | |
| Operating Profit | 21 | 27 | 23 | 22 | 32 | |
| Profit before tax | 18 | 23 | 23 | 21 | 31 | |
| Net Profit | 16 | 17 | 17 | 16 | 23 | |
| EPS in Rs | 36.72 | 41.04 | 35.76 | 33.60 | 48.38 |
Profit & Loss
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 267 | 317 | 394 | 470 | |
| Operating Profit | 56 | 66 | 81 | 102 | |
| Interest | 7 | 7 | 12 | 12 | |
| Depreciation | 20 | 27 | 39 | 46 | |
| Profit before tax | 49 | 62 | 71 | 94 | |
| Net Profit | 37 | 46 | 55 | 70 | |
| EPS in Rs | 78.55 | 98.64 | 116.28 | 147.02 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 |
| Reserves | 109 | 152 | 205 | 341 |
| 232 | 268 | 333 | 326 | |
| Long term borrowings | 36 | 44 | 82 | 67 |
| Short term borrowings | 8 | 7 | 15 | 15 |
| 44 | 71 | 71 | 94 | |
| Trade payables | 27 | 32 | 25 | 27 |
| Current liabilities | 55 | 81 | 87 | 111 |
| Total Liabilities | 390 | 496 | 613 | 766 |
| 325 | 417 | 507 | 581 | |
| Gross block | 423 | 540 | 598 | 695 |
| Accumulated depreciation | 97 | 123 | 91 | 114 |
| Goodwill & intangibles | 1 | 1 | 28 | 28 |
| CWIP | 66 | 102 | 142 | 206 |
| -1 | -23 | -36 | -21 | |
| Inventories | 6 | 10 | 13 | 14 |
| Trade receivables | 10 | 13 | 14 | 19 |
| Cash & equivalents | 27 | 33 | 10 | 7 |
| Current assets | 47 | 60 | 55 | 137 |
| Total Assets | 390 | 496 | 613 | 766 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 70 | 90 | 94 | 145 | |
| Profit for the year | 37 | 46 | 55 | 70 |
| Working capital changes | 5 | 10 | -7 | 6 |
| Direct taxes paid | -12 | -14 | -20 | -9 |
| -71 | -70 | -133 | -174 | |
| Fixed assets purchased | -70 | -71 | -103 | -98 |
| Fixed assets sold | 0 | 1 | 0 | 1 |
| Investments purchased | -12 | -74 | ||
| 0 | -14 | 17 | 25 | |
| Proceeds from borrowings | 21 | 15 | 56 | |
| Repayment of borrowings | -9 | -8 | -11 | -15 |
| Interest paid | -2 | -0 | -3 | -1 |
| Dividends paid | -1 | -3 | -2 | -3 |
| Net Cash Flow | -1 | 6 | -23 | -4 |
| Free Cash Flow | -1 | 18 | -9 | 47 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 32.6% | 34.3% | 29.8% | 25.2% |
| ROCE | — | 16.8% | 16.7% | 15.8% | 16.1% |
| Operating margin | — | 21.2% | 20.9% | 20.6% | 21.7% |
| Net margin | — | 13.8% | 14.6% | 13.9% | 14.9% |
| Debt / equity | — | 2.05 | 1.71 | 1.59 | 0.94 |
| Current ratio | — | 0.84 | 0.74 | 0.63 | 1.23 |
| Debtor days | — | 14 | 15 | 13 | 15 |
| Inventory days | — | 36 | 50 | 55 | 51 |
| Days payable | — | 160 | 165 | 101 | 97 |
| Cash conversion cycle | — | -110 | -100 | -33 | -31 |
| Working capital days | — | -12 | -24 | -30 | 20 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 82.33%
- Institutions (FII, DII, funds) 1.84%
- Public & others 15.83%
Key dates
- Ex-dividend date
- 2 Sep 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Questions about Dr. Agarwal's Eye Hospital Limited
What is the share price of Dr. Agarwal's Eye Hospital Limited today?
What is the market cap of Dr. Agarwal's Eye Hospital Limited?
What is the P/E ratio of Dr. Agarwal's Eye Hospital Limited?
Is Dr. Agarwal's Eye Hospital Limited a good investment?
How can I buy Dr. Agarwal's Eye Hospital Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.